ACADIA Pharmaceuticals Overview

  • Year Founded
  • 1993

Year Founded

  • Status
  • Public

  • Employees
  • 610

Employees

  • Stock Symbol
  • ACAD

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $14.87
  • (As of Tuesday Closing)

ACADIA Pharmaceuticals General Information

Description

Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Contact Information

Website
www.acadia.com
Formerly Known As
Receptor Technologies, Inc.
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 12830 El Camino Real
  • Suite 400
  • San Diego, CA 92130
  • United States
+1 (858) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ACADIA Pharmaceuticals Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$14.87 $14.84 $14.55 - $33.99 $2.46B 165M 1.62M -$0.01

ACADIA Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 2,664,965 4,851,702 2,204,362 3,277,580
Revenue 813,806 726,437 517,235 484,145
EBITDA 6,619 (62,718) (218,028) (164,766)
Net Income (1,710) (61,286) (215,975) (167,870)
Total Assets 855,103 748,956 587,812 700,122
Total Debt 59,642 57,205 62,000 64,430
Public Fundamental Data provided by Morningstar, Inc. disclaimer

ACADIA Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ACADIA Pharmaceuticals‘s full profile, request access.

Request a free trial

ACADIA Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to add
Pharmaceuticals
San Diego, CA
610 As of 2024
00000
000000&0

000000

e dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla p
0000 000000000
Coral Gables, FL
000 As of 0000
00000
00000000 00000

000000

amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et
0000000000000
New York, NY
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ACADIA Pharmaceuticals Competitors (63)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Catalyst Pharmaceuticals Corporation Coral Gables, FL 000 00000 00000000 00000
Axsome Therapeutics Corporation New York, NY 000 00000 00000000 00000
SAGE Therapeutics Formerly VC-backed Cambridge, MA 000 00.000 000000000 00.000
Krystal Biotech Formerly VC-backed Pittsburgh, PA 000 00000 000000000 00000
Dicerna Pharmaceuticals Formerly VC-backed Lexington, MA 000 00000 000000&0 00000
You’re viewing 5 of 63 competitors. Get the full list »

ACADIA Pharmaceuticals Patents

ACADIA Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202209195-D0 Modulators of g protein-coupled receptor 88 Inactive 22-Jun-2022 0000000000
GB-202209193-D0 Modulators of g protein-coupled receptor 88 Inactive 22-Jun-2022 0000000000
US-20230023114-A1 Crystalline forms of trofinetide Active 12-Jul-2021 0000000000
US-11827600-B2 Crystalline forms of trofinetide Active 12-Jul-2021 0000000000 00
CA-3224298-A1 Crystalline forms of trofinetide Pending 12-Jul-2021 C07D207/16
To view ACADIA Pharmaceuticals’s complete patent history, request access »

ACADIA Pharmaceuticals Executive Team (37)

Name Title Board Seat Contact Info
Stephen Davis JD Chief Executive Officer, President & Board Member
Mark Schneyer Chief Financial Officer, Finance & Executive Vice President
Brendan Teehan Chief Operating Officer, Operations & Executive Vice President
James Kihara Chief Accounting Officer, Accounting & Controller, Finance
Rob Ackles Chief People Officer & Senior Vice President
You’re viewing 5 of 37 executive team members. Get the full list »

ACADIA Pharmaceuticals Board Members (15)

Name Representing Role Since
Adora Ndu ACADIA Pharmaceuticals Board Member 000 0000
Daniel Soland Self Board Member 000 0000
Edmund Harrigan MD Self Board Member 000 0000
Elizabeth Garofalo MD Self Board Member 000 0000
Julian Baker Self Board Member 000 0000
You’re viewing 5 of 15 board members. Get the full list »

ACADIA Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ACADIA Pharmaceuticals Investments & Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Neuren (Global Rights in NNZ-2591 in Rett syndrome and Fragile X syndrome) 13-Jul-2023 000000000 00.000 Buildings and Property 0000000 0
CerSci 01-Aug-2020 Merger/Acquisition 000.00 Biotechnology 0000000 0
To view ACADIA Pharmaceuticals’s complete investments and acquisitions history, request access »

ACADIA Pharmaceuticals Subsidiaries (1)

Company Name Industry Location Founded
Levo (Biotechnology) Biotechnology Skokie, IL 0000
To view ACADIA Pharmaceuticals’s complete subsidiaries history, request access »

ACADIA Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated March, 20, 2024

24.06 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,191

Rank

00.0

Percentile

Pharmaceuticals

Industry

00 of 921

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 405

Rank

00.00

Percentile

To view ACADIA Pharmaceuticals’s complete esg history, request access »

ACADIA Pharmaceuticals FAQs

  • When was ACADIA Pharmaceuticals founded?

    ACADIA Pharmaceuticals was founded in 1993.

  • Who is the CEO of ACADIA Pharmaceuticals?

    Stephen Davis JD is the CEO of ACADIA Pharmaceuticals.

  • Where is ACADIA Pharmaceuticals headquartered?

    ACADIA Pharmaceuticals is headquartered in San Diego, CA.

  • What is the size of ACADIA Pharmaceuticals?

    ACADIA Pharmaceuticals has 610 total employees.

  • What industry is ACADIA Pharmaceuticals in?

    ACADIA Pharmaceuticals’s primary industry is Pharmaceuticals.

  • Is ACADIA Pharmaceuticals a private or public company?

    ACADIA Pharmaceuticals is a Public company.

  • What is ACADIA Pharmaceuticals’s stock symbol?

    The ticker symbol for ACADIA Pharmaceuticals is ACAD.

  • What is the current stock price of ACADIA Pharmaceuticals?

    As of 18-Jun-2024 the stock price of ACADIA Pharmaceuticals is $14.87.

  • What is the current market cap of ACADIA Pharmaceuticals?

    The current market capitalization of ACADIA Pharmaceuticals is $2.46B.

  • What is ACADIA Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for ACADIA Pharmaceuticals is $814M.

  • Who are ACADIA Pharmaceuticals’s competitors?

    Catalyst Pharmaceuticals, Axsome Therapeutics, SAGE Therapeutics, Krystal Biotech, and Dicerna Pharmaceuticals are some of the 63 competitors of ACADIA Pharmaceuticals.

  • What is ACADIA Pharmaceuticals’s annual earnings per share (EPS)?

    ACADIA Pharmaceuticals’s EPS for 12 months was -$0.01.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »